CBUS Corporation's Q2 2025 Financial Results Speech Transcription
Cibus, Inc. (CBUS) held a Financial Results and Business Update Conference Call and Webcast on August 14, 2025, at 4:30 PM ET. The conference call participants included Cornelis Broos, Interim Chief Financial Officer, Gregory F. Gocal, Co-Founder, Chief Scientific Officer & Executive VP, and Peter R. Beetham, Co-Founder, Interim CEO, President, COO & Director from Cibus, Inc.
The call was organized to discuss the second quarter 2025 results of Cibus, Inc. The company reported challenging earnings, with a net loss ranging from about $26.6 million to $55.45 million. Revenue growth was weak, approximately $1.26 to $1.38 million, and operating costs were high, particularly in R&D ($25 million) and marketing ($16.31 million).
Despite the losses, Cibus is focusing on high-potential areas. The company is streamlining its operations to focus on Rice herbicide tolerance traits (HT1 and HT3), with planned launches in Latin America (2027) and the US (2028). These launches aim for potential annual royalties over $200 million.
Progress has been made in sustainable ingredients programs, with initial revenues expected in 2025. Cibus also successfully raised $27.5 million through a public offering in June 2025, bringing the cash position to about $36.5 million, expected to fund operations through Q2 2026.
Cost optimization initiatives, including workforce reduction, have been established to reduce annual cash burn to $30 million by 2026. Regulatory support was received with the USDA designating one herbicide tolerance trait (HT2) as not regulated under biotechnology regulations, aiding commercialization prospects.
The market reaction to these results was negative, with shares falling roughly 13% over three days post-earnings, underperforming peers who showed positive returns. The analyst outlook remains cautious due to the pre-commercial stage of Cibus’s products, dependency on regulatory approvals, field trials, and successful commercialization of gene-edited traits.
Investors should watch closely for updates on product launches, regulatory milestones, and whether the company meets its cost reduction goals in the coming quarters. The full Q2 2025 earnings call transcript is not directly available in the provided sources, but key points from recent reports and business updates are summarized here.
The webcast link, press release, and corporate presentation are available on the Investor Relations section of cibus.com.
Read also:
- Catastrophe at a U.S. Steel facility in Pennsylvania results in the loss of two lives. crucial details unveiled
- Manipulating Sympathy: Exploiting Victimhood for Personal Gain
- Auto Industry Updates: Geotab, C2A, Deloitte, NOVOSENSE, Soracom, and Panasonic in Focus
- Exploring Money-Making Opportunities in Digital Gaming Worlds
